title: Protective effect of post-ischemic treatment with trans-resveratrol on cytokine production and neutrophil recruitment by rat liver.
abstract: Oxidative and inflammatory processes are elicited during hepatic post-ischemic reperfusion and generate liver damage. This study investigated the early anti-inflammatory effect of trans-resveratrol (T-res) and its consequences on the late self-aggravating inflammatory process in liver ischemia-reperfusion (I/R). Partial hepatic ischemia was initiated in rats for 1 h and T-res (0.02 and 0.2 mg/kg) was administered intravenously 5 min before starting reperfusion for 3 h. Plasma levels of aminotransferases and cytokines (tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6) and hepatic neutrophil recruitment were assessed. Hepatic expression of stress protein (heat-shock protein (HSP-70), heme oxygenase-1(HO-1)) and cytokine (TNF-alpha, IL-1beta, keratinocyte chemoattractant (KC)) mRNA was investigated. I/R caused an increase in aminotransferase levels and increased polymorphonuclear cell infiltration. Post-ischemic treatment with T-res (0.02 and 0.2 mg/kg) resulted in a significant decrease in aminotransferase, IL-1beta and IL-6 plasma levels by about 40%, 60% and 40%, respectively, compared to the vehicle I/R group. Post-ischemic treatment with T-res (0.02 mg/kg) also significantly decreased hepatic neutrophil recruitment. TNF-alpha, IL-1beta, KC and HO-1 hepatic mRNA expression was reduced by T-res without any change in HSP-70 mRNA. This T-res mediated decrease in early release of cytokines and neutrophil recruitment led to a reduction in the late inflammatory process. T-resveratrol might be useful in the prevention of inflammation secondary to hepatic surgery or liver transplantation.
authors.affiliation: Equipe d'Accueil 3617, Faculté de Pharmacie, Université Paris Descartes, 4 avenue de l'Observatoire, Paris, France.
authors.forename: Sahar
authors.initials: S
authors.lastname: Hassan-Khabbar
authors.forename: Michel
authors.initials: M
authors.lastname: Vamy
authors.forename: Charles-Henry
authors.initials: CH
authors.lastname: Cottart
authors.forename: Dominique
authors.initials: D
authors.lastname: Wendum
authors.forename: Françoise
authors.initials: F
authors.lastname: Vibert
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Savouret
authors.forename: Patrice
authors.initials: P
authors.lastname: Thérond
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Clot
authors.forename: Anne-Judith
authors.initials: AJ
authors.lastname: Waligora
authors.forename: Valérie
authors.initials: V
authors.lastname: Nivet-Antoine
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D019743:Chemokines, CXC / Q000097:blood; D051547:Heme Oxygenase-1 / Q000097:blood; D053583:Interleukin-1beta / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D008297:Male; D020556:Neutrophil Infiltration; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000503:physiopathology*; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D019743:Chemokines, CXC; D053583:Interleukin-1beta; D015850:Interleukin-6; D012333:RNA, Messenger; D013267:Stilbenes; D014409:Tumor Necrosis Factor-alpha; D051547:Heme Oxygenase-1; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000077185:Resveratrol